Potential use of Oncostatin M in Critically ill Patients with acute Kidney Injury
DOI:
https://doi.org/10.3889/oamjms.2024.11803Keywords:
Oncostatin M, acute kidney injuryAbstract
BACKGROUND: Acute kidney injury (AKI) is one of the most common complications affecting patients admitted to intensive care unit (ICU) worldwide. In response to injury, both kidneys and liver secrete acute phase reactants as a mechanism of protection. Oncostatin M (OSM) is a member of the interleukin-6 family of cytokines which was found to be elevated during renal injury as in diabetic nephropathy, glomerulonephritis, and obstructive nephropathy.
AIM: The study aimed to assess the role of OSM as an early biomarker of AKI in critically ill patients.
PATIENTS AND METHODS: We conducted a prospective case–control study that included 202 patients admitted to ICU within Kasr El-Aini University hospitals during the period between January 2022 and August 2022. Eligible patients were divided into two groups according to the occurrence of AKI, and Oncostatin was assessed in the sera of the included patients.
RESULTS: Our findings showed that the AKI group had statistically significant lower OSM levels compared to the control group, especially among those patients who had poor clinical outcomes and non-survivors. We also found that OSM is a good predictive tool for the prediction of mortality among patients admitted to ICU with sepsis complicated with AKI (Area under the curve = 0.673, 95% confidence interval: 0.532–0.814) with a sensitivity of 83.8% and specificity of 61.4%.
CONCLUSION: OSM plays an important role among critically ill patients who are admitted to the ICU with sepsis, it can significantly predict AKI development and subsequent mortality.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Makris K, Spanou L. Acute kidney injury: Definition, pathophysiology and clinical phenotypes. Clin Biochem Rev. 2016;37(2):85-98. PMid:28303073
Magno AL, Herat LY, Carnagarin R, Schlaich MP, Matthews VB. Current knowledge of IL-6 cytokine family members in acute and chronic kidney disease. Biomedicines. 2019;7(1):19. https://doi.org/10.3390/biomedicines7010019 PMid:30871285 DOI: https://doi.org/10.3390/biomedicines7010019
Luyckx VA, Cairo LV, Compston CA, Phan WL, Mueller TF. Oncostatin M pathway plays a major role in the renal acute phase response. Am J Physiol Renal Physiol. 2009;296(4):F875-83. https://doi.org/10.1152/ajprenal.90633.2008 PMid:19158344 DOI: https://doi.org/10.1152/ajprenal.90633.2008
Nechemia-Arbely Y, Barkan D, Pizov G, Shriki A, Rose- John S, Galun E, et al. IL-6/IL-6R axis plays a critical role in acute kidney injury. J Am Soc Nephrol. 2008;19(6):1106-15. https://doi.org/10.1681/ASN.2007070744 PMid:18337485 DOI: https://doi.org/10.1681/ASN.2007070744
Gong Y, Yan X, Sun X, Chen T, Liu Y, Cao J. Oncostatin M Is a prognostic biomarker and inflammatory mediator for sepsis. J Infect Dis. 2020;221(12):1989-98. https://doi.org/10.1093/infdis/jiaa009 PMid:31930328 DOI: https://doi.org/10.1093/infdis/jiaa009
West NR, Hegazy AN, Owens BM, Bullers SJ, Linggi B, Buonocore S, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017;23(5):579-89. https://doi.org/10.1038/nm.4307 PMid:28368383 DOI: https://doi.org/10.1038/nm.4307
O’Hara KA, Kedda MA, Thompson PJ, Knight DA. Oncostatin M: An interleukin-6-like cytokine relevant to airway remodelling and the pathogenesis of asthma. Clin Exp Allergy. 2003;33(8):1026- 32. https://doi.org/10.1046/j.1365-2222.2003.01714.x PMid:12911774 DOI: https://doi.org/10.1046/j.1365-2222.2003.01714.x
Midhuna K, Adole PS, Vinod KV, Balamurugan N. Association of serum regenerating islet-derived protein 3-beta and oncostatin-M levels with the risk of acute coronary syndrome in patients with type 2 diabetes mellitus-a pilot study. Diabetes Metab Syndr. 2020;14(5):1087-92. https://doi.org/10.1016/j.dsx.2020.06.026 PMid: 32652496 DOI: https://doi.org/10.1016/j.dsx.2020.06.026
Hoste EA, Kellum JA, Selby NM, Zarbock A, Palevsky PM, Bagshaw SM, et al. Global epidemiology and outcomes of acute kidney injury. Nat Rev Nephrol. 2018;14(10):607-25. https://doi.org/10.1038/s41581-018-0052-0 PMid:30135570 DOI: https://doi.org/10.1038/s41581-018-0052-0
Pothoven KL, Norton JE, Hulse KE, Suh LA, Carter RG, Rocci E, et al. Oncostatin M promotes mucosal epithelial barrier dysfunction, and its expression is increased in patients with eosinophilic mucosal disease. J Allergy Clin Immunol. 2015;136(3):737-46.e4. https://doi.org/10.1016/j.jaci.2015.01.043 PMid:25840724 DOI: https://doi.org/10.1016/j.jaci.2015.01.043
Liang H, Block TM, Wang M, Nefsky B, Long R, Hafner J, et al. Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. Cancer Biomark. 2012;11(4):161-71. https://doi.org/10.3233/CBM-2012-00276 PMid:23144154 DOI: https://doi.org/10.3233/CBM-2012-00276
Den Hoedt CH, Bots ML, Grooteman MP, Van Der Weerd NC, Mazairac AH, Penne EL, et al. Online hemodiafiltration reduces systemic inflammation compared to low-flux hemodialysis. Kidney Int. 2014;86(2):423-32. https://doi.org/10.1038/ki.2014.9 PMid:24552852 DOI: https://doi.org/10.1038/ki.2014.9
Nakada TA, Oda S, Matsuda KI, Sadahiro T, Nakamura M, Abe R, et al. Continuous hemodiafiltration with PMMA Hemofilter in the treatment of patients with septic shock. Mol Med. 2008;14(5):257-63. https://doi.org/10.2119/2007-00108.Nakada PMid:18327291 DOI: https://doi.org/10.2119/2007-00108.Nakada
Downloads
Published
How to Cite
License
Copyright (c) 2024 Amin Soliman, Nora Mahmoud Ali Selim, Motaz Esam El-din Abdel-Motelb, Rasha Ahmed Darwish, Ahmed Soliman (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
